Practice Test Geeks(CCDM) Certified Clinical Data Manager Practice Test
← All CCDM Flashcard Decks

Regulatory Requirements Flashcards

7 cards from real CCDM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Regulatory Requirements flashcards as text

  1. According to ICH E6 R2, what must be included in the clinical trial agreement between a sponsor and a Contract Research Organization (CRO)?

    Answer: A written specification of all trial-related duties and functions transferred to the CRO

    ICH E6 R2 requires that agreements between sponsors and CROs include a written specification of all duties and functions being transferred.

  2. Under 21 CFR Part 312, what is an Investigational New Drug (IND) application primarily designed to allow?

    Answer: A sponsor to ship an investigational drug across state lines for clinical testing

    An IND allows a sponsor to legally transport and administer an investigational drug in interstate commerce for clinical trial purposes before FDA approval.

  3. Which of the following scenarios would constitute a protocol deviation rather than a protocol violation?

    Answer: A scheduled visit occurring one day late due to a holiday

    Minor, unintentional, non-significant departures from the protocol such as a visit one day late are typically classified as deviations rather than violations.

  4. What does the Declaration of Helsinki primarily establish for clinical research?

    Answer: Ethical principles for medical research involving human subjects

    The Declaration of Helsinki establishes the foundational ethical principles guiding medical research involving human participants, emphasizing participant welfare above scientific interests.

  5. In clinical data management, what is the primary regulatory purpose of maintaining an audit trail in an EDC system?

    Answer: To document all changes to data fields with who made them, when, and why

    Audit trails ensure data integrity by recording all changes to clinical data, including the original value, new value, user identity, timestamp, and reason for change.

  6. Which FDA guidance document describes the agency's current thinking on risk-based monitoring for clinical investigations?

    Answer: FDA Guidance on Risk-Based Monitoring (2013)

    The FDA's 2013 guidance on oversight of clinical investigations introduced a risk-based approach to monitoring as an alternative to traditional 100% source data verification.

  7. Under GDPR, which legal basis is most commonly used for processing clinical trial participant data in the EU?

    Answer: Public interest in the area of public health

    GDPR Article 9(2)(i) allows processing of special category health data for public interest reasons in the area of public health, commonly applied to clinical research.